112 related articles for article (PubMed ID: 35548328)
1. Correction: MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment.
Yang J; Liao C; Liu Y; Yang G; Ke T; Ding Y; Li Q
Oncotarget; 2022; 13():641. PubMed ID: 35548328
[TBL] [Abstract][Full Text] [Related]
2. MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment.
Yang J; Liao C; Liu Y; Yang G; Ke T; Ding Y; Li Q
Oncotarget; 2018 Feb; 9(15):11964-11976. PubMed ID: 29552285
[TBL] [Abstract][Full Text] [Related]
3. Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti-angiogenic treatment.
Pan F; Li W; Yang W; Yang XY; Liu S; Li X; Zhao X; Ding H; Qin L; Pan Y
Oncol Lett; 2018 Sep; 16(3):3083-3091. PubMed ID: 30127899
[TBL] [Abstract][Full Text] [Related]
4. Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy.
Zhang L; Takara K; Yamakawa D; Kidoya H; Takakura N
Cancer Sci; 2016 Jan; 107(1):36-44. PubMed ID: 26475217
[TBL] [Abstract][Full Text] [Related]
5. Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2020 Oct; 11(41):3749-3750. PubMed ID: 33110482
[TBL] [Abstract][Full Text] [Related]
6. Correction: Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort.
Akinyemiju T; Moore JX; Dibaba DT; Pisu M; Goodman M; Howard VJ; Safford M; Gilchrist SC; Cushman M; Long L; Judd SE
Oncotarget; 2020 Feb; 11(7):758. PubMed ID: 32133050
[TBL] [Abstract][Full Text] [Related]
7. Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?
Eyre TA
Oncotarget; 2019 Feb; 10(17):1661. PubMed ID: 30899436
[TBL] [Abstract][Full Text] [Related]
8. Correction: Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies.
Ma F; Dai L; Wang Z; Zhou L; Niu Y; Jiang N
Oncotarget; 2018 Jun; 9(49):29285. PubMed ID: 30018753
[TBL] [Abstract][Full Text] [Related]
9. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
[TBL] [Abstract][Full Text] [Related]
10. Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth.
Hanson K; Robinson SD; Al-Yousuf K; Hendry AE; Sexton DW; Sherwood V; Wheeler GN
Oncotarget; 2018 Nov; 9(93):36645. PubMed ID: 30564304
[TBL] [Abstract][Full Text] [Related]
11. Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SL; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
Oncotarget; 2018 Apr; 9(28):20219. PubMed ID: 29733074
[TBL] [Abstract][Full Text] [Related]
12. Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.
Hu Y; Yu T; Liu X; He Y; Deng L; Guo J; Hua Y; Luo T; Gao X
Oncotarget; 2020 Sep; 11(37):3484-3485. PubMed ID: 32973972
[TBL] [Abstract][Full Text] [Related]
13. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
14. Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer.
Guido BC; Brandão DC; Barbosa ALA; Vianna MJX; Faro L; Ramos LM; Nihi F; de Castro MB; Neto BAD; Corrêa JR; Báo SN
Oncotarget; 2022; 13():1068. PubMed ID: 36187557
[TBL] [Abstract][Full Text] [Related]
15. Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Oncotarget; 2019 Aug; 10(49):5120-5122. PubMed ID: 31489122
[TBL] [Abstract][Full Text] [Related]
16. Erratum: Publisher Correction to
BioMed Central
EJNMMI Radiopharm Chem; 2018 Dec; 3():13. PubMed ID: 31329807
[TBL] [Abstract][Full Text] [Related]
17. Correction: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II.
Mazumder S; Swank V; Komar AA; Johnson JM; Tuohy VK
Oncotarget; 2022; 13():905-906. PubMed ID: 35937501
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Publisher Correction to: Multiple articles in Food Science and Biotechnology.
Publisher
Food Sci Biotechnol; 2018 Aug; 27(4):1245. PubMed ID: 30265261
[TBL] [Abstract][Full Text] [Related]
19. Correction: Non-invasive
Peng BY; Chiou CS; Dubey NK; Yu SH; Deng YH; Tsai FC; Chiang HS; Shieh YH; Chen WH; Deng WP
Oncotarget; 2018 May; 9(38):25383. PubMed ID: 29863193
[TBL] [Abstract][Full Text] [Related]
20. Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.
Shapovalova M; Davydova J; Henzler C; Daniel M; Dehm SM; Warlick CA; LeBeau AM
Oncotarget; 2019 Aug; 10(47):4920. PubMed ID: 31448058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
